Dr. Mohammad Hajimolaali

I obtained my Ph.D. in Pharmaceutics from the University of Patras, Greece, in 2025. I possess several years of extensive experience across diverse sectors of the pharmaceutical manufacturing industry, with particular expertise in quality control systems, liposomal drug delivery systems, and pharmaceutical formulation development.

My doctoral research focused on the design and development of hyaluronic acid lipid-conjugate coated liposomes for targeted drug delivery to triple-negative breast cancer. The study involved comprehensive in vitro evaluation using established cellular models to assess targeting efficiency, cytotoxicity, and cellular uptake.

EDUCATION

I obtained my Ph.D. in Pharmaceutics from the University of Patras, Greece, in 2025.

RESEARCH, TEACHING, or OTHER INTERESTS

Pharmacy, Chemistry, General Pharmacology, Toxicology and Pharmaceutics, Arts and Humanities

RECENT SCHOLAR PUBLICATIONS

Applications of immunochemotherapy based on smart nanocarriers in gastric cancer
S Askari Vaselabadi, M Hajimolaali, M Dehghani, A Bagheri, M Ghidar, ...
Micro Nano Bio Aspects 4 (4), e239510 , 2025
2025
Anti-diabetic, anti-inflammatory, antioxidant, anticancer, antimicrobial, and tissue engineering applications of genipin compound in micro-and nanoformulations: A mini-review
Z Taheri, M Hajimolaai, M Vafaei
Micro Nano Bio Aspects 3 (4), 13-18 , 2024
2024
Citations: 1
Hyaluronic acid lipid-conjugate coated liposome for targeted delivery of drugs to triple negative breast cancer: in-vitro evaluation on cellular models
M Hajimolaali
University of Patras, Greece. (***PhD Thesis***) , 2024
2024
Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy
M Hajimolaali, FA Dorkoosh, SG Antimisiaris
Journal of Liposome Research 34 (4), 671-696 , 2024
2024
Citations: 28
Antibacterial and antioxidant activity of catechin, gallic acid, and epigallocatechin-3-gallate: focus on nanoformulations
M Alavi, MR Hamblin, E Aghaie, SAR Mousavi, M Hajimolaali
Cellular, Molecular and Biomedical Reports 3 (2), 62-72 , 2023
2023
Citations: 38
Industrial-scale methods for the manufacture of liposomes and nanoliposomes: pharmaceutical, cosmetic, and nutraceutical aspects
M Alavi, MR Mozafari, MR Hamblin, M Hamidi, M Hajimolaali, I Katouzian
Micro Nano Bio Aspects 1 (2), 26-35 , 2022
2022
Citations: 55
Polysaccharide-based biomaterials: delivery of therapeutics and biomedical applications
S Jana, S Jana, AJ Domb
Royal Society of Chemistry , 2022
2022
Citations: 12
Hyaluronic acid in drug delivery
N Maghsoudnia, RB Eftekhari, M Roshandel, M Ahmadi, M Edalat, ...
2022
Citations: 2
Liposomal supplements
N Maghsoudnia, M Edalat, M Hajimolaali, S Iranpour, P Khoshkhat, ...
Liposomes for functional foods and nutraceuticals, 235-278 , 2022
2022
Citations: 7
Liposomes for functional foods and nutraceuticals: from research to application
S Gopi, P Balakrishnan
CRC Press , 2022
2022
Citations: 9
Application of chloroquine as an endosomal escape enhancing agent: new frontiers for an old drug
M Hajimolaali, H Mohammadian, A Torabi, A Shirini, M Khalife Shal, ...
Expert Opinion on Drug Delivery 18 (7), 877-889 , 2021
2021
Citations: 57
Antibiotic utilization in Iran 2000–2016: Pattern analysis and benchmarking with organization for economic co-operation and development Countries
SZ Hadi Abbasian1, Mohammad Hajimolaali2, Alireza Yektadoost1
Journal of Research in Pharmacy Practice 8 (3), 162-167 , 2019
2019
Citations: 63
Despite affordability, low utilization of lipid lowering drugs in Iran: Trend analysis and benchmarking 2005-2016
S Zartab, H Abbassian, NN Koopaei, M Hajimolaali
Iranian Journal of Pharmaceutical Research: IJPR 18 (2), 1117 , 2019
2019
Citations: 2
A new approach in identifying and evaluating quality risks in the pharmaceutical industry in Iran
M Hajimolaali
Tehran University of Medical Sciences. (***Master Thesis***) , 2017
2017
A new approach in identifying and evaluating quality risks in the pharmaceutical industry ,
M Hajimolaali
Tehran University of Medical Sciences, TUMS , 2017
2017
Citations: 9
Quality risk assessment production of beta lactams by FMEA model and fuzzy theory method
M Hajimolaali, AA Asl
Gen Med (Los Angel) 4 (1), 1-3 , 2016
2016
Citations: 6

MOST CITED SCHOLAR PUBLICATIONS

Antibiotic utilization in Iran 2000–2016: Pattern analysis and benchmarking with organization for economic co-operation and development Countries
SZ Hadi Abbasian1, Mohammad Hajimolaali2, Alireza Yektadoost1
Journal of Research in Pharmacy Practice 8 (3), 162-167 , 2019
2019
Citations: 63
Application of chloroquine as an endosomal escape enhancing agent: new frontiers for an old drug
M Hajimolaali, H Mohammadian, A Torabi, A Shirini, M Khalife Shal, ...
Expert Opinion on Drug Delivery 18 (7), 877-889 , 2021
2021
Citations: 57
Industrial-scale methods for the manufacture of liposomes and nanoliposomes: pharmaceutical, cosmetic, and nutraceutical aspects
M Alavi, MR Mozafari, MR Hamblin, M Hamidi, M Hajimolaali, I Katouzian
Micro Nano Bio Aspects 1 (2), 26-35 , 2022
2022
Citations: 55
Antibacterial and antioxidant activity of catechin, gallic acid, and epigallocatechin-3-gallate: focus on nanoformulations
M Alavi, MR Hamblin, E Aghaie, SAR Mousavi, M Hajimolaali
Cellular, Molecular and Biomedical Reports 3 (2), 62-72 , 2023
2023
Citations: 38
Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy
M Hajimolaali, FA Dorkoosh, SG Antimisiaris
Journal of Liposome Research 34 (4), 671-696 , 2024
2024
Citations: 28
Polysaccharide-based biomaterials: delivery of therapeutics and biomedical applications
S Jana, S Jana, AJ Domb
Royal Society of Chemistry , 2022
2022
Citations: 12
Liposomes for functional foods and nutraceuticals: from research to application
S Gopi, P Balakrishnan
CRC Press , 2022
2022
Citations: 9
A new approach in identifying and evaluating quality risks in the pharmaceutical industry ,
M Hajimolaali
Tehran University of Medical Sciences, TUMS , 2017
2017
Citations: 9
Liposomal supplements
N Maghsoudnia, M Edalat, M Hajimolaali, S Iranpour, P Khoshkhat, ...
Liposomes for functional foods and nutraceuticals, 235-278 , 2022
2022
Citations: 7
Quality risk assessment production of beta lactams by FMEA model and fuzzy theory method
M Hajimolaali, AA Asl
Gen Med (Los Angel) 4 (1), 1-3 , 2016
2016
Citations: 6
Hyaluronic acid in drug delivery
N Maghsoudnia, RB Eftekhari, M Roshandel, M Ahmadi, M Edalat, ...
2022
Citations: 2
Despite affordability, low utilization of lipid lowering drugs in Iran: Trend analysis and benchmarking 2005-2016
S Zartab, H Abbassian, NN Koopaei, M Hajimolaali
Iranian Journal of Pharmaceutical Research: IJPR 18 (2), 1117 , 2019
2019
Citations: 2
Anti-diabetic, anti-inflammatory, antioxidant, anticancer, antimicrobial, and tissue engineering applications of genipin compound in micro-and nanoformulations: A mini-review
Z Taheri, M Hajimolaai, M Vafaei
Micro Nano Bio Aspects 3 (4), 13-18 , 2024
2024
Citations: 1
Applications of immunochemotherapy based on smart nanocarriers in gastric cancer
S Askari Vaselabadi, M Hajimolaali, M Dehghani, A Bagheri, M Ghidar, ...
Micro Nano Bio Aspects 4 (4), e239510 , 2025
2025
Hyaluronic acid lipid-conjugate coated liposome for targeted delivery of drugs to triple negative breast cancer: in-vitro evaluation on cellular models
M Hajimolaali
University of Patras, Greece. (***PhD Thesis***) , 2024
2024
A new approach in identifying and evaluating quality risks in the pharmaceutical industry in Iran
M Hajimolaali
Tehran University of Medical Sciences. (***Master Thesis***) , 2017
2017